

**STUDY OF PLASMA ENDOTHELIN-1 LEVEL
IN LIVER CIRRHOSIS AND
HEPATORENAL SYNDROME**

THESIS
SUBMITTED FOR PARTIAL FULFILMENT
OF THE M.D. DEGREE IN
CLINICAL AND CHEMICAL PATHOLOGY

By

Azza Abdel-Karim El-Tagoury
M.B.B.Ch. & M.S. Clinical Pathology
Faculty of Medicine - Ain Shams University

616.0756
A.P.

7073

SUPERVISORS



Prof. Dr. Mahmoud Sabry Sallam
Prof. of Clinical and Chemical Pathology
Ain Shams University

Dr. Nadia Aly Abdel-Sattar
Assistant Prof. of Clinical and Chemical Pathology
Ain Shams University

Dr. Ola Hamdy Demerdash
Assistant Prof. of Clinical and Chemical Pathology
Ain Shams University

Dr. Dalia Helmy Farag
Lecturer of Clinical and Chemical Pathology
Ain Shams University

Faculty of Medicine
Ain Shams University





ACKNOWLEDGMENT

I WISH TO EXPRESS MY DEEPEST GRATITUDE AND APPRECIATION TO PROFESSOR DR. MAHMOUD SABRY SALLAM, PROFESSOR OF CLINICAL PATHOLOGY, AIN SHAMS UNIVERSITY FOR HIS CONSISTENT SUPERVISION AND VALUABLE SUGGESTION. HE OFFERED AS FAR AS CHANCES PERMITTED AND ABOVE ALL FOR HIS MORAL SUPPORT. WITHOUT HIS HELP, THE WHOLE WORK WOULD NOT HAVE BEEN POSSIBLE.

I'M ALSO SO GRATEFUL TO DR. NADIA ALY ABDEL-SATTAR, ASSISTANT PROFESSOR OF CLINICAL PATHOLOGY, AIN SHAMS UNIVERSITY FOR HER TRUSTFUL HELP, KINDNESS AND UNFAILING ADVICE.

I WOULD LIKE TO OFFER A SPECIAL GRATITUDE TO DR. OLA HAMDY DEMERDASH, ASSISTANT PROFESSOR OF CLINICAL PATHOLOGY, AIN SHAMS UNIVERSITY FOR HER KEEN INTEREST AND SUPERVISION. I'M SO GRATEFUL TO SINCERITY IN EFFORT AND TIME OFFERED BY HER.

I WISH TO EXPRESS MY DEEP APPRECIATION TO DR. DALIA HELMY FARAG, LECTURER OF CLINICAL PATHOLOGY, AIN SHAMS UNIVERSITY FOR HER KIND HELP AND SINCERE ADVICE.

SINCERE THANKS ARE ALSO DUE TO DR. MAHMOUD ZAKI, LECTURER OF MEDICINE, AIN SHAMS UNIVERSITY FOR HIS HELP AND SUPPORT.

TO ALL THE STAFF OF CLINICAL CHEMISTRY DEPARTMENT, I WISH TO GIVE MY GRATITUDE PERSONALLY FOR EACH, ESPECIALLY FOR BIOCHEMIST AHMED KAMAL FOR HIS GREAT HELP.

LIST OF FIGURES

Figure	Page No.
1. Vasoactive substances released from the vascular endothelium	5
2. Amino acid sequence of ET-1, ET-2 and ET-3	15
3. Synthetic pathway for production of the endothelins (ET)	19
4. Generation and actions of ET-1 in the blood vessel wall	38
5. Regression analysis showing correlation between age and ET-1 among group-1 patients	143
6. Regression analysis showing correlation between creatinine clearance and ET-1 among group-1 patients	144
7. Regression analysis showing correlation between ALP and ET-1 among group-2 patients	145
8. Regression analysis showing correlation between GGT and ET-1 among group-2 patients	146
9. Comparative study between different studied groups regarding creatinine clearance	147
10. Comparative study between different studied groups regarding BUN	148
11. Comparative study between different studied groups regarding endothelin-1 levels	149
12. Comparative study between different studied groups regarding serum creatinine	150
13. Comparative study between different studied groups regarding serum total proteins	151
14. Comparative study between different studied groups regarding serum albumin	152

LIST OF TABLES

Table	Page No.
1. ET receptor mapping in vivo	27
2. Plasma ET-1 levels in different age groups	35
3. Biological actions of endothelin peptides	61
4. Possible causes of renal vasoconstriction in hepatorenal syndrome	96
5. List of standard concentrations	122
6. Descriptive statistics for control group	133
7. Descriptive statistics for group-I patients (cirrhosis)	133
8. Descriptive statistics for group-II patients (acute renal failure)	134
9. Descriptive statistics for group-III patients (hepatorenal failure)	134
10. Comparative statistical study between control and group I patients (cirrhosis group)	135
11. Comparative statistical study between control and group II patients (acute renal failure group)	135
12. Comparative statistical study between control and group III patients (hepatorenal failure group)	136
13. Comparative statistical study between cirrhosis and acute renal failure groups	136
14. Comparative statistical study between cirrhosis and hepatorenal failure groups	137
15. Comparative statistical study between acute renal failure and hepatorenal failure group	137
16. Statistical comparison between different studied groups regarding plasma ET-1 using logistic "t" test	138
17. Correlation study between ET-1 and all studied parameters for group-I (cirrhosis) using ranked Sperman correlation test	139
18. Correlation study between ET-1 and all studied parameters for group-II (acute renal failure) using ranked Sperman correlation test	139
19. Correlation study between ET-1 and all studied parameters for group-III (hepatorenal failure) using ranked Sperman correlation test	140
20. Analysis of variance for all patient groups (parameters were sorted in descending order according to their F-ratio)	141
21. Raw data for control group	i
22. Raw data for liver cirrhosis with ascites	iii
23. Raw data for liver cirrhosis without ascites	v
24. Raw data for acute renal failure	vii
25. Raw data for hepatorenal failure	ix

ABBREVIATIONS

ET	Endothelin
PGI₂	Prostacyclin
ATP	Adenyl triphosphate
ADP	Adenyl diphosphate
NO	Nitric oxide
EDRF	Endothelium derived relaxing factor
cGMP	Cyclic guanosine monophosphate
cAMP	Cyclic adenosine monophosphate
A-II	Angiotensin-II
t-PA	Tissue plasminogen activator
EDHF	Endothelium-derived hyperpolarizing factor
ACE	Angiotensin converting enzyme
PAF	Platelet activating factor
[Ca²⁺]_i	Intracellular calcium
[Ca²⁺]	Ionized calcium
GFR	Glomerular filtration rate
RBF	Renal blood flow
TXA₂	Thromboxane A ₂
VIC	Vasoactive intestinal contractor
S6b	Sarafotoxin 6 b
APR	Acute phase reactant
TGF-β	Transforming growth factor β
AU	Adenosine uracil
Lys	lysine
Arg	Arginine
Cys	Cysteine
Met	Methionine
Tryp	Tryptophan
Ile	Isoleucine
ECE	Endothelin converting enzyme
ET-1-LI	Endothelin-1 like immunoreactivity
PMN	Polymorphonuclear
ANP	Atrial natriuretic peptide
TNF	Tumor necrosis factor
IL-1	Interleukin-1
PLC	Phospholipase C
PI	Phosphatidyl inositide
IP	Inositol phosphate
PKC	Protein kinase C

EC	Extracellular
IC	Intracellular
EGTA	Ethyl glycol tetra-acetic acid
ROC	Receptor operated channel
VOC	Voltage operated channel
PLA2	Phospholipase A2
NEP	Neutral endopeptidase
SNFR	Single nephron filtration rate
RAS	Renin angiotensin system
ADH	Antidiuretic hormone
EDCF	Endothelium derived contracting factor
ARF	Acute renal failure
RIA	Radioimmunoassay
EIA	Enzyme immunoassay
CLIA	Chemiluminescence immunoassay
POD	Peroxidase
TFA	Trifloro acetic acid
HPLC	High performance liquid chromatography
ATN	Acute tubular necrosis
AST	Aspartate amino transferase
ALT	Alanine amino transferase
ALP	Alkaline phosphatase
GGT	Gammaglutamyl transferase
HRS	Hepatorenal syndrome
FeNa	Fractional excretion of sodium
COP	Cardiac output
GIT	Gastrointestinal tract
MAO	Monoamine oxidase
AV	Arteriovenous
EDTA	Ethylene diamine tetra acetic acid
KIU	Kallikrein inhibitory unit

CONTENTS

INTRODUCTION AND AIM OF THE WORK	1
REVIEW OF LITERATURE	
<i>I. Vasoactive factors</i>	
A. Endothelium derived vasodilators	
1. Prostacyclin	4
2. Nitric oxide	6
3. Endothelium-derived hyperpolarizing factor	9
B. Endothelium derived vasoconstrictors	
1. Platelet activating factor	11
2. Thromboxane A ₂	12
3. Endothelin "ET"	12
<i>II. Endothelin:</i>	
A. ET family and structure	14
B. Molecular genetics	17
C. Biosynthesis	20
D. Regulation of production	22
E. Sites of production	24
F. Release	26
G. Binding sites and receptors	27
H. Plasma concentration	32
I. Physiological variation	34
J. Mechanisms of action	37
K. Clearance and metabolism	47
L. Effects	49
M. Role of ET in the pathogenesis of some clinical disorders	60
N. Therapeutic role of anti-endothelins	71
<i>III. Methods of assays</i>	
A. Bioassay	
1. In vivo bioassay	73
2. In vitro bioassay	74
3. Immunohistochemistry	76

B. Immunoassay	
1. RIA	76
2. EIA	78
3. CLEIA	79
C. Methods of extraction	
IV. Liver cirrhosis and hepatorenal syndrome	
A. Liver cirrhosis	
1. Definition	83
2. Classification	84
3. Clinical cirrhosis and its types	84
4. Clinical picture and sequelae of cirrhosis	86
B. HRS	
1. Definition	90
2. Clinical features	92
3. Lab findings	92
4. Diagnosis and differential diagnosis	93
5. Pathogenesis	94
6. Treatment	104
SUBJECTS AND METHODS	105
RESULTS	130
DISCUSSION	153
SUMMARY AND CONCLUSION	164
REFERENCES	168
ARABIC SUMMARY	

**INTRODUCTION
AND
AIM OF THE WORK**

Introduction:

Endothelin (ET) is a recently discovered circulating polypeptide consisting of 21 amino acids. Three isoforms have been identified; ET (1,2,3) (*Inoue et al., 1989*)a.

Endothelial cells produce exclusively ET-1 (*Saito et al., 1989*). ET-1 produces a profound and sustained contractile response (*Yanagisawa et al., 1988*). This effect occurs through rising of the intracellular free Ca^{++} and increasing the inositol phosphate turnover (*Marsden et al., 1989*).

Elevated plasma concentrations of endothelin have been reported in patients with acute renal failure (*Firth et al., 1988*), subarachnoid hemorrhage (*Masaoka et al., 1989*), myocardial infarction (*Miyauchi et al., 1989*), chronic renal failure, hypertension (*Shichiri et al., 1990*) and sepsis (*Pittet et al., 1991*).

Endothelial cells of various origin synthesize endothelin. It is therefore likely that the hepatic endothelial and Kupffer cells, which are the predominant cell types constituting liver sinusoids also synthesize this peptide (*Yanagisawa et al., 1988 and Takahashi et al., 1989*).

Under conditions of hypoxia and vascular tissue damage, endothelial cells are stimulated to synthesize and secrete endothelin (*Firth et al., 1988*). Accordingly, in cases of liver injury leading to hepatic hypoxia, the hepatic endothelial cells also generate this peptide. Since this peptide produces a powerful renal and systemic vasoconstriction, such effects may mediate the development of renal failure in patients with severe liver disease (*King et al., 1989*).

Aim of the work:

The aim of the present work is to study plasma endothelin levels in patients with liver cirrhosis with and without ascites, acute renal failure and hepatorenal syndrome in a trial to find out the clinical significance of endothelin in the various studied diseased groups as well as its possible role in the pathogenesis of the hepatorenal syndrome.